- Crystal Pharmatech has introduced the ELDICO ED-1 microcrystal electron diffractometer and expanded its collaboration with ELDICO Scientific AG.
- The ED-1 will be installed at the company’s Suzhou R&D site, enabling MicroED integration into routine solid-state workflows for global clients.
Crystal Pharmatech has announced the introduction of the ELDICO ED-1 microcrystal electron diffractometer and the expansion of its collaboration with ELDICO Scientific AG. The system will be installed at the company’s R&D site in Suzhou, China, where it will support global clients with Microcrystal Electron Diffraction (MicroED) capabilities for pharmaceutical development.
The deployment positions Crystal Pharmatech as the first company in China and the Asia-Pacific region to implement a dedicated MicroED platform designed for industrial applications. The ED-1 enables direct determination of crystal structures from sub-micron crystalline powders for small-molecule compounds and is designed for automated, continuous operation.
The platform is intended to support solid-state research workflows, including polymorph, salt, and cocrystal screening, as well as characterization of amorphous solid dispersions and detection of trace polymorphic impurities. By integrating MicroED into routine processes, the company aims to enable high-throughput and reproducible analysis for drug development programs.
“Integrating the ELDICO ED-1 into our platform represents a major step toward making MicroED a routine tool in pharmaceutical development.”
Alex Chen, Co-founder, Chairman & CEO of Crystal Pharmatech
The collaboration builds on an existing partnership between Crystal Pharmatech and ELDICO Scientific AG in solid-state research and crystallography applications. The company stated that the investment supports its efforts to expand analytical capabilities across the drug development lifecycle within its CRO and CDMO and contract manufacturing services.
